Review in Advances in pharmacology (San Diego, Calif.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
2 authors.
Angela M LeeDepartment of Psychiatry, Yale University, New Haven, CT, United States; Yale Interdepartmental Neuroscience Program, New Haven, CT, United States.
Marina R PicciottoDepartment of Psychiatry, Yale University, New Haven, CT, United States; Yale Interdepartmental Neuroscience Program, New Haven, CT, United States. Electronic address: marina.picciotto@yale.edu.
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Yale/NIDA Neuroproteomics Research CenterP30DA018343 · NIDA · YALE UNIVERSITY · PI Marina R Picciotto · 2004 to 2026
$37.1M
Yale-SCORE Resource Support CoreU54AA027989 · NIAAA · YALE UNIVERSITY · PI Sherry Ann McKee · 2020 to 2026
$13.0M
Cholinergic Contribution to Circuits Underlying DepressionR01MH077681 · NIMH · YALE UNIVERSITY · PI MINEUR, YANN SEBASTIEN, PICCIOTTO, MARINA R · 2006 to 2025
$7.0M
Acetylcholine signaling allows cognitive processes in the brain to regulate physiological responses to the environment: the example of central control of opiate toleranceDP1DA050986 · NIDA · YALE UNIVERSITY · PI PICCIOTTO, MARINA R · 2019 to 2023
$5.9M
Anatomical basis for nicotine addiction in miceR01DA014241 · NIDA · YALE UNIVERSITY · PI PICCIOTTO, MARINA R · 2001 to 2018
$5.2M
Anatomical Basis for Nicotine AddictionR37DA014241 · NIDA · YALE UNIVERSITY · PI Marina R Picciotto · 2020 to 2026
$2.7M
Sex differences in noradrenaline andstress-induced reinstatement of nicotine CPPF30DA043943 · NIDA · YALE UNIVERSITY · PI LEE, ANGELA MISUN · 2017 to 2018
Paul Greengard brought to neuroscience the idea of, and evidence for, the role of second messenger systems in neuronal signaling. The fundamental nature of his contributions is evident in the far reach of his work, relevant to various subfields and topics in neuroscience. In this review, we discuss some of Greengard's work from the perspective of nicotinic acetylcholine receptors and their relevance to nicotine addiction. Specifically, we review the roles of dopamine- and cAMP-regulated phospho-protein of 32kDa (DARPP-32) and Ca
Indexed as
Signal TransductionAnimalsBehavior, AddictiveCalcium-Calmodulin-Dependent Protein Kinase Type 2Dopamine and cAMP-Regulated Phosphoprotein 32HumansNicotineReceptors, NicotinicCalcium-Calmodulin-Dependent Protein Kinase Type 2Dopamine and cAMP-Regulated Phosphoprotein 32NicotineReceptors, NicotinicAddictionCalciumCaMKIIcAMPDARPP-32Nicotine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addiction. · full record | OpenQuestion